Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€21.13

€21.13

-2.160%
-0.465
-2.160%
€31.98
 
25.07.25 / Tradegate WKN: 852009 / Symbol: PFE / Name: Pfizer / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Pfizer Inc. Stock

We can see a decrease in the price for Pfizer Inc.. Compared to yesterday it has lost -€0.465 (-2.160%).
With 21 Buy predictions and 3 Sell predictions Pfizer Inc. is one of the favorites of our community.
With a target price of 31 € there is a positive potential of 46.75% for Pfizer Inc. compared to the current price of 21.13 €.
Our community identified positive and negative aspects for Pfizer Inc. stock for the coming years. 15 users see the criterium "Worthwhile Investment for the next years" as a plus for the Pfizer Inc. stock. On the other hand our users think that "Conscious of the environment" could be a problem in the future.

Pros and Cons of Pfizer Inc. in the next few years

Pros
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Cons
?
B****
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Pfizer Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Pfizer Inc. -2.160% 0.356% 1.392% -24.161% -16.732% -58.292% -31.278%
Johnson & Johnson -0.750% 1.761% 9.705% -2.675% 3.063% -15.012% 12.653%
Elanco Animal Health Inc. 0.080% 1.876% 7.712% 7.639% 10.062% -37.064% -37.296%
Biogen Inc. -0.980% 4.089% 2.517% -46.641% -22.249% -44.828% -52.137%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

When diving into the financials of Pfizer Inc. (PFE), a major player within the pharmaceuticals industry, a mixed picture starts to emerge. On the one hand, the company boasts a solid revenue stream and demonstrates a commendable operating margin, creating an impression of profitability. On the other hand, several warning signs appear in the form of declining growth metrics and concerns over income stability. Now, let’s break down the analysis into pros and cons to provide a comprehensive view.

Strong Revenue Performance: Pfizer reported a total revenue of approximately $54.89 billion over the trailing twelve months. This figure suggests that the company has maintained a robust sales figure, driven largely by their pharmaceutical portfolio, including well-known products and newly developed vaccines.

Healthy Operating Margins: The operating margin, standing at around 31.63%, illustrates the company's efficiency in turning sales into profit. This is relatively strong for the pharmaceutical sector, indicating that Pfizer is effectively managing its operating expenses relative to its revenue.

Comments

Prediction Sell
Perf. (%) -2.33%
Target price 19.483
Change
Ends at 03.07.26

Pfizer Inc. (NYSE: PFE) had its price target raised by analysts at Wolfe Research from $22.00 to $23.00. They now have an "underperform" rating on the stock.
Ratings data for PFE provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -2.33%
Target price 22.025
Change
Ends at 03.07.26

Pfizer Inc. (NYSE: PFE) had its price target lowered by analysts at HSBC Holdings plc from $27.00 to $26.00. They now have a "buy" rating on the stock.
Ratings data for PFE provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -2.33%
Target price 27.954
Change
Ends at 03.07.26

Pfizer Inc. (NYSE: PFE) had its price target raised by analysts at Jefferies Financial Group Inc. from $32.00 to $33.00. They now have a "buy" rating on the stock.
Ratings data for PFE provided by MarketBeat
Show more

News

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union


Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has

Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound: https://www.marketbeat.com/logos/articles/med_20250722153159_healthcare-stocks-hit-valuation-bottom-3-names-to.jpg
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound

Today’s stock market focus is centered on one single sector: technology stocks.

The excitement around artificial intelligence (AI) has led to most attention—and capital–being concentrated in one

2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade: https://g.foolcdn.com/editorial/images/824342/doctor-and-patient-talking.jpg
2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade

Pharmaceutical giants Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) have lagged the market over the past year, although Pfizer's poor performance dates back much further. Though these companies